Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, and Oxford Gene Technology (OGT) have announced a collaborative agreement aimed at improving the early detection of pancreatic cancer.
As part of this collaboration, Abcodia will provide data mining expertise to deliver optimal sample sets from its large prospective serum biobank, taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Abcodia will bring their expertise in experimental design and analysis.
Julie Barnes, the Chief Executive Officer, Abcodia said: "We are very excited to be able to form this strategic partnership with OGT. The combination of the breadth of the OGT technology with our unique serum biobank provides a real opportunity to significantly advance the field of early pancreatic cancer diagnosis and screening. ”
John Anson, Vice President Biomarker Discovery, OGT said: "A common challenge in discovering novel cancer biomarkers is the availability of well characterised samples for the disease area of interest. We are delighted that, through our partnership with Abcodia, we are able to employ our unique and integrated genomic and proteomic array technologies to identify sensitive and specific biomarkers for pancreatic cancer."
Financial details were not disclosed.